Evident Vascular has announced the successful closing of its Series B financing with new investors Shangbay Capital and two undisclosed multinational strategics joining founding investor Vensana Capital. A press release details that the funding will accelerate development of the company’s advanced intravascular ultrasound (IVUS) technology designed to enhance vascular imaging and patient outcomes and support 510(k) US Food and Drug Administration (FDA) clearance ahead of US market launch.
“We are proud to continue supporting Evident Vascular, which is at the forefront of innovation in intravascular imaging that has become the standard of care in peripheral vascular and complex coronary interventions,” said Cynthia Yee, partner at Vensana Capital. “Evident’s next-generation IVUS platform represents a transformative step forward in vascular care, offering clinicians powerful tools to enhance diagnosis and guide treatment consistent with clinical evidence and today’s medical guidelines.”
Evident Vascular notes in a press release that its vision is to transform vascular imaging through innovations that expand the adoption of IVUS by increasing its utility and accessibility in clinical practice.
“This significant investment underscores our investors’ confidence in Evident Vascular’s mission and technology while highlighting the vital role of intravascular imaging in optimising patient outcomes, clinical decision-making and procedural success,” stated Howard Rosen, chief executive officer and co-founder of Evident Vascular. “We will accelerate our progress toward FDA clearance and further the development of our AI [artificial intelligence]-powered IVUS solution, which aims to set a new standard in vascular image-guided therapy.”
